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StandardizationChronic kidney disease deﬁnition is based on glomerular ﬁltration rate (GFR) estimations which are derived
from creatinine-based equations. The accuracy of GFR estimation is thus largely dependent of those of serum
creatinine assays. International recommendations highlight the need for traceable creatinine assays. The
French Society of Clinical Biochemistry conducted a study for measuring accuracy of creatinine enzymatic
methods. This evaluation involved 25 clinical laboratories. Creatinine was measured in serum pools ranging
from 35.9±0.9 μmol/L to 174.5±3.1 μmol/L (IDMS determination) using 12 creatinine enzymatic methods.
For all creatinine values greater than 74.4±1.4 μmol/L, the bias and imprecision did not exceed 5% and 5.9%,
respectively. For the lowest value (35.9±0.9 μmol/L), the bias ranged from −1.8 to 9.9% (with one
exception). At this level, the imprecision ranged from 1.9 to 7.8%. The true performances of the assays (couples
of bias and relative standard deviation), were evaluated usingMonte-Carlo simulations. Most of the assays fall
within the maximum Total Error of 12% at all concentrations. This study demonstrates substantial
improvements in the calibration, traceability and precision of the enzymatic methods, reaching the NKDEP
recommendations. Moreover, most of these assays allowed accurate creatinine measurements for creatinine
levels lower than 40 μmol/L.ists; CKD, chronic kidney disease; EC4, European Com
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Chronic kidney disease (CKD) is a major public health problem in
developed countries. Since the ﬁrst proposal for CKD deﬁnition from
the National Kidney Foundation (NKF) Kidney Disease Outcome
Quality Initiative (K/DOQI) in 2002 [1], the concept of a severity-based
international classiﬁcation of renal diseases has been largely accepted
worldwide. Thus, an update for a global deﬁnition was proposed in
2005 by the Kidney Disease Improving Global Outcomes (KDIGO)
foundation [2]. CKD staging directly relies on GFR values which are
mostly estimated by creatinine-based predictive formulas. As a
consequence, the accuracy of GFR estimation, and by the way, those
of serum creatinine (sCr) assays, has become a major topic, common
to clinicians and laboratories.
However, as soon as the K/DOQI classiﬁcation was proposed,
limitations of sCr measurement and the need for standardization have
been highlighted [3]. In 2002, the “Creatinine FrenchWorking Group”
demonstrated that a very high inter-assay variation persisted and that
a standardization of the calibration procedure did not reduce enough
the variability of sCr assays to allow reliable use of estimated GFR [4].
By the same way, a study performed in 2003 by the College of
American Pathologists (CAP) evaluated on fresh frozen serum with a
sCr concentration 79.7 μmol/L (0.902 mg/dL), to verify commutability
among sCr measurement methods. They showed that a signiﬁcant bias
versus isotope dilution mass spectrometry (IDMS) value persisted [5].
More recently, the EC4 (European Communities of Clinical Chemistry)
creatinine standardizationworking group showed that inter-laboratory
variation persisted in reference material prepared from human fresh
serum with sCr at a concentration of 76 μmol/L [6].
Since 2006, the “Laboratory Working Group of the National Kidney
Disease Education Program” (NKDEP) have described recommenda-
tions for improving GFR estimation with guidelines for measuring
serum creatinine [7], highlighting the need for traceable and reproduc-
ible methods for sCr measurement. The Laboratory Working Group
recommended the recalibration of sCr methods in order to be traceable
to IDMS. After recalibration, the desirable total error goal should be less
than 7.6%, at a sCr concentration of 88.4 μmol/L (1 mg/dL), to ensure a
maximum relative 10% increase in the root mean square error of
estimated GFR. They also recommended a serum reference material
with a sCr target value of 88.4 μmol/L, that corresponds to an average
GFR of 60 mL/min/1.73 m2, to be developed. To meet the latter, the
National Institute of Standards and Technology (NIST) has developed a
commutable standard reference material (SRM) 967, with sCr at two
concentrations, 66.5 μmol/L (0.75 mg/dL) and 346.2 μmol/L
(3.93 mg/dL), measured with both GC–MS and LC–MS, in frozen
human serum [8]. This SRM is now available to laboratories and
manufacturers for the calibration and evaluation of routine clinical sCr
methods.
The calibration of sCr methods improved the accuracy of GFR
estimation and Murthy et al. recommended that the GFR would be
estimated below 60 mL/min/1.73 m2 only, unless the method has
been calibrated [9].
Some manufacturers adjusted the calibration to reduce the
contribution of non-creatinine chromogens in the alkaline-picrate-
based methods, primarily by subtracting a constant value as
representing the average non-creatinine-dependent signal (so-called
“compensated” methods). However, the use of these assays is not
accurate on an individual patient basis because of the variability of
these chromogens. The evaluation of GFR with such methods in
everyday practice for children, elderly patients, pregnant women,
cancer or anorectic patients who have low creatinine concentrations
could lead to a huge overestimation of renal function [10,11].
Furthermore, the measurement of creatinine in urinary samples,
which contain no non-creatinine chromogens, does not need a
compensation of the calibration. Consequently, assays based on
enzymatic reactions that are much less susceptible to interfere withPlease cite this article as: Piéroni L, et al, A multicentric evaluation of I
doi:10.1016/j.cca.2011.07.012non-creatinine chromogens may provide more reliable estimations of
GFR.
Since the publication of recommendations, efforts have been made
by manufacturers to improve the performances of their creatinine
measurement methods, particularly with developing enzymatic
methods. To our knowledge, no study has evaluated the performances
of enzymatic methods for creatinine assay, after the publication of
NKDEP recommendations and the development of SRM. The purpose of
SFBC (Société Française de Biologie Clinique) was to check for accuracy
of creatinine enzymatic methods commercially available in France.
2. Material and methods
2.1. Experimental design
This evaluation was performed in 2008 and involved 25 clinical
laboratories located in 23 French public hospitals and in 2 French
private clinical laboratories. sCr was measured in a panel of 5 frozen
serum pools and in a Liquid Assayed Multiqual (LAM) Control Level 1
from BIORAD using 12 creatinine enzymatic methods each corre-
sponding to a combination of a reagent and an analyzer. Each method
was evaluated in 3 different laboratories.
Sample pools were sent frozen along with LAM Control level 1
(batch number 45571, given to be IDMS traceable to 69 μmol/L) by
Pasteur Cerba laboratory (MM) to each laboratory where they were
stored at−20 °C until analysis. All data were centralized for statistical
analysis at Hôpital Lapeyronnie, Montpellier, France (ASB) and CHU
Sart Tilman, Liège, Belgium (ER).
2.2. Serum samples
A panel of ﬁve serum pools was prepared in a central laboratory
(Pr Galteau, Centre de Médecine Préventive, Nancy, France) in order
to cover a wide range of creatinine concentrations from 40 to
200 μmol/L, as previously described [4]. During the preparation, sCr
was measured using the local non compensated Jaffe assay (Olympus
AU 640 using Olympus reagents).
2.3. Principle of enzymatic creatinine methods and details of reagent–
analyzer combinations
We evaluated 10 creatinine enzymatic commercially available
reagents on 9 analyzers. The main characteristics of the 10 reagents
andof the 12 reagent–analyzer combinations are summarized in Table 1.
Enzymatic methods used either creatininase (creatinine amidohydro-
lase EC 3.5.2.10) or creatinine deiminase (creatinine iminohydrolase EC
3.5.4.21).
The ﬁrst type of enzymatic methods uses a reaction scheme to
convert creatinine in sarcosine with the aid of creatininase and
creatinase (creatine amidinohydrolase EC 3.5.3.3) and release of
hydrogen peroxide with the aid of sarcosine oxidase. In the presence
of peroxidase, the liberated hydrogen peroxide reacts by quantitative
oxidation with a leuko dye and is measured via an appropriate
colorimetric reaction.
In the second type of enzymatic methods, creatinine is converted
by creatinine deiminase to ammonia and N-methylhydantoin. The
ammonia is subsequently assayed by use of alpha-oxoglutarate and
glutamate dehydrogenase. The reduction in absorbance at 340 nm,
caused by oxidation of NADPH, is proportional to the ammonia
concentration released by creatinine.
2.4. Pre-analytical step
Both pool samples and LAM Control level 1 were thawed at room
temperature 1 h before analysis, homogenized by gentle inversionDMS-traceable creatinine enzymatic assays, Clin Chim Acta (2011),
Table 1
Main characteristics of the 12 automated sCr method–analyzer combinations.
Analyzers Reagents Enzymes Chromogen Reading
mode
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GC–IDMS



















Siemens Advia 1800 Siemens Creatinine
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N-methylhydantoïne+ammoniac Cinetics 340/410 Bovine serum
0–862 μmol/L








2 points 670 Bovine serum
44–133–1167 μmol/L
NIST SRM 914
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at 4 °C for the next days of analysis.
2.5. Preliminary period
Imprecision studies were conducted using LAM Control level 1
(batch number 45571, IDMS-traceable). Within-run (30 replicates)
and between-run (3 separate runs per day for 10 consecutive days)
values were determined in each laboratory (n=30).
Methods not available in the lab's routine practice were imple-
mented by themanufacturer and submitted to a familiarization period
including intra-assay reproducibility (n=20 determinations) on the
lowest control level provided by the manufacturer.
2.6. Study period
Determinations of the panel were performed on a single batch of
reagents after a new calibration and validation of the performance of
the method using local internal quality control procedures. The 5
pools were assayed on 3 separate runs per day; LAM Control level 1
was run at the start and the end of the run as samples to verify the run.
This test was conducted over 3 consecutive days (1 aliquot thawed
each day).
2.7. Reference method
Isotope dilution-gas chromatography mass spectrometry (GC–
IDMS) was used as the reference method. Determinations were
performed by the Laboratoire National de Métrologie (VD, Paris,
France) as previously described [12].
2.8. Statistical analysis
For each reagent–analyzer combinations and pool, evaluation of
aberrant data (outliers) was performed using mean reagent–analyzer
combination result plus/minus 2 standard deviations. Results werePlease cite this article as: Piéroni L, et al, A multicentric evaluation of I
doi:10.1016/j.cca.2011.07.012discarded only if in addition to the statistical evaluation, analytical
reasons were determined.
For each laboratory, the average value for each level was
calculated. Then these laboratory mean values were grouped per
reagent–analyzer combination. Since the trueness was targeted using
reference method, plots against the target value could be constructed
for each pool level (Fig. 1). Analytical performance was assessed at
three levels: bias from the reference value, between-laboratory and
within laboratory variation.
The following hierarchical mixed linear model was ﬁtted on all the
data to evaluate the ﬁxed effects of creatinine concentrations of the
pools and the random effects of the assays, laboratories and runs as
well as the interaction of the concentration levels with the assays:
yijklm = μ + αi + βj + γk½j + ηl½j;k + αiβj + εijklm:
μ is the overall mean. αi represents the ﬁxed effect of the
concentration levels or creatinine pools (i: 1 to 5), βj represents the
random effect of the assays (j: 1 to 16), γk[j] is the random effect of the
laboratories nested into the assays (k: 1 to 3), ηl[j,k] is the random
effect of the runs nested into the assays and laboratories (l: 1 to 3) and
αiβj is the concentration–assay interaction. All the random effects
were assumed coming from independent central normal distribu-
tions. εijklm is the residual error (or repeatability) assumed normally
distributed N(0,σε2). For the ﬁxed effect, signiﬁcance level was settled
at 5%.
On each pool of creatinine (i=1 to 5), the following random
ANOVA III hierarchical model was ﬁtted in order to evaluate the
importance in terms of % Relative Standard Deviation (RSD) of each
factor assessed, namely: assay kit, laboratory, run and repeatability
(or residual error):
yjklm = μ + βj + γk½j + ηl½ j;k  + εiklm:
Then, computations of relative biases (%) and RSDs (%) for all
assays at all pools of creatinine were computed using the results















A  B C D E F G   J
Results of GC-IDMS from LNE
Pool 5: 174.5 +/-3.1 μmol/L
Pool 4: 149.7 +/-2.9 μmol/L
Pool 3: 97.9 +/-1.7 μmol/L
Pool 2: 74.4 +/-1.4 μmol/L
Pool 1 : 35.9 +/-0.9 μmol/L
LKH I
Fig. 1. Relative bias according to GC–IDMS creatinine in 5 pools ranging from 36 to
175 μmol/L. Twelve methods corresponding to a reagent/analyzer combination were
evaluated. A: Roche Modular/Roche; B: Roche Cobas/Roche; C: Olympus/Randox;
D: OrthoClinical/OrthoClinical; E: Olympus/Diasys; F: Roche Modular/Diasys; G: Siemens
RXL/Siemens; H: Abbott/Abbott; I: Beckman Coulter/Sentinel Diagnostics; J: Thermo-
FischerKonelab/Kone; K: Olympus/Olympus; L: Siemens Advia/Siemens.
4 L. Piéroni et al. / Clinica Chimica Acta xxx (2011) xxx–xxxfor the bias estimations. JMP v7.0.1 (SAS Institute, Cary, NC) software
was used to perform these computations.
Based on these results all the possible true couples of bias and RSD
values for each method at all pools giving 95 times out of 100 theCreatinine - Pool 1 Creatinine
Creatinine - Pool 4 Creatinine
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Fig. 2. Monte-Carlo simulations representing 95% probable regions of true performances of
couples of bias and RSD values that can give a 95% probability of the bias and RSD observe
maximum of 8% Total Error. Dashed curve: region deﬁned by true values of bias and RSD w
Please cite this article as: Piéroni L, et al, A multicentric evaluation of I
doi:10.1016/j.cca.2011.07.012estimated values obtained in the study were searched byMonte-Carlo
simulations. Simultaneously, the true region of couples (bias, RSD)
providing at most 8% Total Error and 12% Total Error was computed
and all these elements were graphed for interpretations. These graphs
plotted systematic bias and imprecision of the reagent–analyzer
combination into a parabolic curve initially developed by Myers et al.
(Fig. 2). These analysis and graphs were performed with R v2.9.1
(CRAN, http://cran.r-project.org).
3. Results
3.1. Target values for the ﬁve pools investigated
According to GC–IDMS, the true creatinine levels of the ﬁve pools
investigatedwere 35.9±0.9 μmol/L, 74.4±1.4 μmol/L, 97.9±1.7 μmol/L,
149.7±2.9 μmol/L and 174.5±3.1 μmol/L for pools 1, 2, 3, 4 and 5,
respectively.
3.2. Sources of variability
The hierarchical linear mixed model ﬁtted well the whole set of
data as shown by the high value of the adjusted R² equal to 0.998. The
concentration levels of creatinine were found highly statistically
signiﬁcant (p-valueb0.0001), revealing that the results of the assays
were dependent of the true concentrations of the pools. Furthermore
the interaction coefﬁcient between concentration levels and assays
was also highly signiﬁcant (p-value b0.0001) demonstrating that all
the assays were not responding similarly when the creatinineRoche Diagnostic/Roche Modular
Roche Diagnostic/Roche Cobas 6000
Randox/Olympus 2700
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the assays for different pools of creatinine. Monte-Carlo simulations represent the true
d in the study. Continuous curve: region deﬁned by true values of bias and RSD with a
ith a maximum of 12% Total Error.
DMS-traceable creatinine enzymatic assays, Clin Chim Acta (2011),
5L. Piéroni et al. / Clinica Chimica Acta xxx (2011) xxx–xxxconcentration increases. The random effects of assays, lab runs and
repeatability measured as RSDs showed that the assays were
responsible of the most variability in the results (RSD=1.5%)
together with the laboratories (RSD=1.5%), whereas the runs and
repeatability parts were the smallest with similar levels (RSD of 0.5
and 0.4%, respectively). This illustrates that the results of creatinine
can be highly different from one assay to the other, as well as from one
laboratory to the other (data not shown).
3.3. Analytical performances (imprecision and bias according to the
reference method)
To deepen the analysis, the bias of each assay was computed by
comparison to the results obtained by the national reference
laboratory as well as the imprecision of each assay. The results of
imprecision for each pool of creatinine are illustrated in Table 2.
For the lowest pool (35.9±0.9 μmol/L) the bias ranged from−1.3 to
18.8% and the imprecision from 1.9 to 7.3%. The minimum and
maximum biases were observed for the assays Abbott on Architect
and OrthoClinicalDiagnostics on Fusion 5.1, respectively. Themaximum
imprecisionwas observed for the Sentinel reagents on BeckmanCoulter
LX. For all other pools, the observed bias never exceed 5%, ranging from
−4.5% (OrthoClinicalDiagnostics, pool 4) to 3.8% (OrthoClinicalDiag-
nostics, pool 2). Similarly, the imprecision ranged from 0.70% (Abbott
Architect, pool 4) to 5.9% (Beckman Coulter LX, pool 2).
3.4. True performances of the assays deﬁned by bias and RSD
Based on these observed performances of the assays expressed in
terms of couples of bias and RSD, the true performance of the assays
were searched by Monte-Carlo simulations. They represent all the
true couples of bias and RSD values of the assays that can give the
observed values of bias and RSD of the study 95 times out of 100. The
results are shown in Fig. 2 for each pool of creatinine. Furthermore,
the regions of methods deﬁned by their true values of bias and RSD
that have a maximum of 8% Total Error (desirable creatinine assays:
continuous line) and a maximum of 12% Total Error (acceptable
creatinine assays: dotted line) as proposed by Myers are depicted on
these graphs [7]. The assays that answer these speciﬁcations of
maximum 8% and 12% Total Error are thus those falling inside these
regions. As shown in Fig. 2, far from all the assays fall within the
maximum Total Error of 12% at all the concentrations of creatinine.
Only four reagent/analyzer combinations do not ﬁt this requirement
at the ﬁrst level of 35 μmol/L (Ortho Clinical/Ortho Clinical Fusion 5.1,
ThermoFisher/ThermoFisher Konelab, Sentinel Diagnostics/Beckman
Coulter LX20 and Diasys/Olympus AU 2700).Table 2
Imprecision between laboratories. Imprecision expressed as relative SD% according to diffe









Pool 1 Mean 37.43 35.43 36.87 42.66 38.53 38.08
SD 0.91 1.17 2.04 1.71 2.82 1.08
CV% 2.43 3.31 5.53 4.01 7.33 2.84
Pool 2 Mean 75.12 73.74 75.95 77.12 74.96 75.77
SD 1.01 1.65 2.98 1.55 4.28 2.14
CV% 1.34 2.24 3.93 2.01 5.71 2.82
Pool 3 Mean 99.73 97.83 101.20 98.77 99.59 99.92
SD 1.23 1.99 3.47 2.26 4.50 2.38
CV% 1.24 2.04 3.43 2.28 4.52 2.38
Pool 4 Mean 150.64 149.49 152.3 142.99 150.58 149.80
SD 1.86 3.65 4.59 3.89 2.63 2.96
CV% 1.23 2.44 3.01 2.72 1.74 1.98
Pool 5 Mean 176.02 173.84 179.67 167.71 175.37 175.55
SD 1.94 2.48 5.98 5.27 3.71 3.08
CV% 1.10 1.43 3.33 3.14 2.11 1.75
Please cite this article as: Piéroni L, et al, A multicentric evaluation of I
doi:10.1016/j.cca.2011.07.012At the second level of 74 μmol/L, three of these four reagent/analyzer
combinations are on the 12% borderline but all the other meet the
speciﬁcations.
4. Discussion
In this study, we have shown and illustrated the substantial
improvements in the calibration, traceability and precision for most of
the enzymatic methods used for creatinine measurement. This study
demonstrates for the ﬁrst time that NKDEP recommendations could
be achieved using enzymatic creatinine assays. Moreover, most of
these assays allowed accurate creatinine measurements for creatinine
levels lower than 40 μmol/L.
The calibration matter for creatinine is especially relevant because
creatinine is more and more automatically used by laboratories to
estimate GFR, notably with the Modiﬁcation of the Diet in Renal
Disease (MDRD) study equations [7,13–16]. The impact of the
calibration on the MDRD results is far from negligible, especially in
the high GFR range [7,9,17–19]. The MDRD study equation has even
beenmodiﬁed to be useful with IDMS traceable creatinine [13,15]. The
need for a traceable, reproducible, method for sCr measurement could
be further enhanced using CKD-EPI (Chronic Kidney Disease Epide-
miology Collaboration) formula taking into account low creatinine
value (lower than 62 μmol/L for women) [20].
Several authors have illustrated the lack of standardization for
creatinine measurement until now. One of the most descriptive
studies is certainly the study published in 2005 by Miller on behalf of
College of American Pathologists [5]. Comparing ﬁfty methods of
creatinine measurement in 5624 American laboratories with a
reference method (IDMS), these authors ﬁnd large discrepancies
and bias between the methods. Creatinine results with different
enzymatic methods differ from the reference method from −1.8 to
17.7 μmol/L (−0.02 to 0.2 mg/dL). In this study, only one level of
creatinine was studied and the statistical weight of methods differ
from each other allowing the number of laboratories using a method–
analyzer combination (for example, the picrate method from Roche is
used by 78 laboratories whereas the picrate method from Olympus is
only used in 12 laboratories) [5]. Other studies in France [4] and
United Kingdom [18] have also underlined the lack of standardization
and the high inter-assay and inter-laboratory CV.
Another important study on this topic has been published in 2006
by Myers on behalf of the NKDEP Laboratory Working Group [7]. This
working group has determined the total analytical error in creatinine
that may be considered as acceptable (total error budget). This total
error combines the systematic bias, due to differences of calibration,
and the randommeasurement error which includeswithin-laboratoryrent creatinine pools and reagent/analyzer combinations.




KoneLab AU 2700 Advia
1800
35.24 35.90 37.93 39.45 37.78 36.71
1.73 0.66 2.95 2.19 0.84 0.75
4.93 1.85 7.78 5.57 2.23 2.06
71.72 71.58 76.16 77.12 75.02 73.97
2.19 1.16 4.47 1.75 1.46 1.54
3.06 1.62 5.87 2.28 1.94 2.08
96.00 95.40 99.50 101.20 98.81 97.41
2.89 1.45 3.97 1.59 2.59 1.85
3.01 1.52 3.99 1.57 2.62 1.89
144.79 145.70 151.47 148.37 148.46 146.83
3.48 0.98 2.89 6.15 1.95 2.55
2.40 0.67 1.91 4.14 1.31 1.74
169.04 169.54 176.66 176.51 173.36 172.21
2.86 4.01 3.73 4.29 2.12 3.08
1.69 2.36 2.11 2.43 1.22 1.78
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6 L. Piéroni et al. / Clinica Chimica Acta xxx (2011) xxx–xxxeffect, between-laboratory random variability in day-to-day calibra-
tion and specimen-speciﬁc effect. Myers calculated desirable total
error of 7.6%. This assumption is based on the intra- and inter-
individual biological variation of creatinine [7]. This concept was
reported in 2008 by Delanghe who has conducted a similar study than
Miller in Europe. Three levels of creatinine were analyzed by 189
laboratories. Among these laboratories, 30% were measuring creati-
nine with an enzymatic method but only 3 reagent–analyzer
combinations. In this study, the budget of the total error was
especially consumed by the systematic bias. This fact is especially
relevant in enzymatic methods because the random measurement
error is low with these methods [6]. Indeed, analytical performances
of the enzymatic creatinine measurement are clearly better than for
the classical Jaffe methods [10,11]. Interferences such as bilirubin or
hemolysis also seem less important with enzymatic methods, as it has
been elegantly shown by Cobbaert [10].
According to these previous data, we have focused our work on
these enzymatic methods. Moreover, it is evident that the impact of
the analytical error in creatinine measurement is only relevant in the
relatively low levels of creatinine. We have thus studied ﬁve
creatinine levels insisting on the low levels of creatinine. This study
has been conducted in 2008. At this time, the creatinine calibration
problems were well known, had been extensively illustrated in the
literature and were well known by all scientists, clinical biologists,
nephrologists and manufacturers [11,21]. Most of the manufacturers
have claimed to have improved their calibration to the IDMS [21,22].
The main ﬁnding of our study is that enzymatic methods have
improved their calibration to IDMS creatinine and reached a relative
bias lower than 5% at level up to 70 μmol/L as recommended by
NKDEP. Furthermore, using a low creatinine level (36 μmol/L), the
relative bias is lower than 10% except for dry chemistry. The marked
bias differences between OrthoClinical Diagnostics reagents and other
creatininase assays strongly suggest that the positive bias in the dry
chemistry method could be due to difference in calibration. This
observation conﬁrms and extends Delanghe's previous report show-
ing a constant overestimation using dry chemistry. Interestingly, after
Delanghe's work, performed in 2005 [6], OrthoClinical Diagnostics has
recalibrated its assay leading to an IDMS traceable creatinine. This
process prevents the overestimation in value greater than 77 μmol/L
(0.87 mg/dL), but has to be further improved for low values. It could
be hypothesized that this speciﬁc dry chemistry bias could be, at least
in part, due to a matrix effect or use of bovine materials.
Our study clearly evidences an improvement in creatininemeasure-
ments in comparison to other studies in the recent past. Indeed, our
results demonstrated that themajority of enzymatic methods reach the
total analytical error of 8% as demonstrated by the Monte-Carlo
simulation. It seems fundamental to underline that such results are
obtained for creatinine values as low as 36 μmol/L (0.41 mg/dL).
Our study has several strengths. We have studied more than 12
reagent–analyzer combinations (25 laboratories have participated) on
ﬁve different levels of creatinine. Our comparison has been realized
against a valid and strong referencemethod andwe used frozen human
sera to avoid matrix effect [23,24]. Contrary to other studies, each
method has been studied and validated in the same number of
laboratories and with the same methodology which makes easier
statistical interpretations [5,6]. However, there are some limitations.We
have tried to be exhaustive in the choice of the enzymatic methods but
some methods have been omitted either because not enough
laboratories using this method could be included or because the
methodswere still not available when the study has been designed.We
have validated creatininemeasurement in the low concentration range.
However, we have no proof that precision and calibration are linear and
performing well between 0 and 36 μmol/L. These low values are
however only important in pediatrics [10]. As previously shown, we
conﬁrm that precision (random error measurement) of enzymatic
methods is high formost of themethods. However, for theﬁrst time, wePlease cite this article as: Piéroni L, et al, A multicentric evaluation of I
doi:10.1016/j.cca.2011.07.012can afﬁrm that several enzymatic methods are adequately calibrated
against IDMS, substantially improving standardization and traceability
of this renal marker. This “good news” will have important conse-
quences on the precision of the estimated GFR by the creatinine-based
equations [16].Acknowledgments
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